Using light and sound therapy to treat Alzheimer's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of a light and sound device that stimulates the brain at 40Hz on individuals with mild Alzheimer's disease. Participants will use the device at home daily for six months, with their progress monitored through EEG, blood tests, microbiome analysis, MRI scans, and cognitive assessments during three in-person visits. The goal is to determine if this therapy can enhance gamma wave activity in the brain, reduce toxic protein deposits, and improve memory function. The study aims to recruit 60 participants, including a small cohort of early-onset Alzheimer's patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Subjects may be enrolled into the study if they meet all of the following criteria:

* Subject is between the ages of 65 - 100.
* Subject must have mild Alzheimer's disease with a Mini Mental State Exam (MMSE) score of 19-26.
* Subject is willing to sign informed consent document.
* If subject is deemed to not have capacity to sign the informed consent, he/she will need a legally authorized representative to provide surrogate consent.
* Able to complete the 1st month of at home stimulation at their primary residence. If subjects plan to spend more than 1 week away from their primary residence during the trial, their inclusion must be assessed by the research team.

Exclusion Criteria:

Subjects who meet any of the following conditions will not be enrolled in the study:

* Subjects who do not have healthcare.
* Subjects who are currently taking amyloid reducing therapy.
* Subjects who have \> 4 cerebral microbleeds or 1 macrobleed in their brain
* Active treatment on a dosage of one or more psychiatric agents (e.g. antidepressants, antipsychotics, etc) for LESS THAN three months (a stable dose for greater than or equal to three months is ok).
* Subjects who are actively diagnosed with cancer and undergoing cancer-related treatments
* Subjects who are being treated with N-methyl-D-aspartate (NMDA) receptor antagonists (eg. Memantine).
* Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc.
* Subjects with history of seizure or epilepsy
* Subjects with clinically significant suicide risk and/or suicide attempt in the past 1 year.
* Subjects with behavioral problems such as aggression/agitation/impulsivity that might interfere with their ability to comply with protocol.
* Subjects with untreated or unstable depression
* Active treatment with one or more anti-epileptic agent.
* Subjects who have had a stroke within the past 24 months.
* Subjects who have had eye surgery in the last 3 months or are scheduled to have eye surgery in the next 6 months (during the study)
* Subjects diagnosed with migraine headache.
* Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and/or sacral nerve stimulator.
* Subjects who have profound hearing or visual impairment.
* Subjects who have a life expectancy of less than 2 years.
* Subjects who are pregnant.
* Current or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis) or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment.

Where it's running

• Massachusetts Institute of Technology
  Cambridge, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Li Huei Tsai, PhD — Massachusetts Institute of Technology
• Study coordinator: gamma wave
• Email: gamma.wave@mit.edu
• Phone: 617-258-7723

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biobank for studying ALS and Alzheimer's diseases

  This study is collecting blood, skin samples, and health information from people to see how genetics might help us understand and find treatments for ALS and Alzheimer's disease.

  Recruiting New York Stem Cell Foundation Research Institute · New York, New York · NCT06203106

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Brain stimulation plus methylphenidate for apathy in Alzheimer's

  This trial will test whether combining short sessions of noninvasive brain stimulation (intermittent theta burst) with methylphenidate can reduce apathy in people with Alzheimer's disease or mixed Alzheimer's/vascular dementia.

  Recruiting Phase 2 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT07279740

• Targeted magnetic stimulation of the precuneus to slow cognitive decline in Alzheimer's

  This will try repetitive magnetic brain stimulation of the precuneus to see if it slows memory and thinking decline in people aged 50–85 with biomarker-confirmed mild Alzheimer's.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam · NCT07036328

• Improving symptoms of mild cognitive impairment and early dementia with brain stimulation

  This study is testing a new brain stimulation treatment combined with mental exercises to see if it can help people with mild cognitive impairment and early dementia feel better.

  Recruiting University of Campania Luigi Vanvitelli · Caserta, Italy · NCT06668610

• Time-restricted eating intervention for Alzheimer's disease

  This study is testing if eating only during a 14-hour window at night can help people with Mild Cognitive Impairment or early Alzheimer's disease think better and sleep more soundly.

  Recruiting Phase 1 University of California, San Diego · San Diego, California · NCT06548191

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.